J&J boosts US investments by 25% to over $55 billion - Breaking The News

J&J boosts US investments by 25% to over $55 billion

21 March

1 min read

EPA-EFE/JUSTIN LANE

Johnson and Johnson (J&J) announced on Friday in a press release that it will up its investments in the United States to more than $55 billion over the next four years, a 25% jump compared to the previous four-year period.

"Today's announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world's toughest healthcare challenges. Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina," CEO Joaquin Duato said.

Apart from the North Carolina facility, the company is putting money into new advanced manufacturing facilities and the expansion of several existing sites across the Innovative Medicine and MedTech businesses; further investing in research and development (R&D) infrastructure; and investing more in technology.

johnson & johnson

Related Stocks

Johnson & Johnson

J&J's Q4 sales beat estimates, up 5.3% to $22.5B

22 January

Johnson and Johnson (J&J) revealed on Wednesday that its total sales in the closing quarter of fiscal 2024 landed at $22.5 billion, booking a 5.3% growth compared to the prior-year quarter. The figure came in slightly above the market estimates. Meanwhile, its diluted earnings per share fell 17.1% year-over-year, coming in at $1.41 in the reported quarter. Full-year sales climbed by 4.3% to $88.8 billion compared to the year before. Net earnings...

J&J to buy Intra-Cellular Therapies in $14.6B deal

13 January

Johnson & Johnson announced on Monday that it reached an agreement to buy biopharmaceutical company Intra-Cellular Therapies Inc. for around $14.6 billion or $132 per share in cash. J&J said it will fund the deal through a combination of cash on hand and debt and will provide an update on the potential impact of the acquisition on its adjusted earnings per share during the fourth quarter earnings call on January 22.The transaction is expected to be...

J&J's Q3 sales rise by 5.2% to $22.5B

15 October

Johnson & Johnson reported on Tuesday that its sales for the third quarter increased by 5.2% on a yearly basis, reaching $22.5 billion. Net earnings plunged 37.5% to $2.7 billion, with the diluted earnings per share (EPS) down 34.3% to $1.11. "Johnson & Johnson’s strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation," CEO Joaquin Duato said.The company updated its...

J&J: Over $2B to be put into new facility in North Carolina

1 October

Johnson & Johnson unveiled on Tuesday in a press release that it will be investing $2 billion in North Carolina to build a "state-of-the-art biologics manufacturing facility."Vice President of Innovative Medicine Supply Chain Dapo Ajayi stated that having a "strong, global supply chain" is of utmost importance and added that with this investment the company further ensures its transformational medicines can be delivered to patients "reliably and...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.